

Edgar Filing: SYNAPTIC PHARMACEUTICAL CORP - Form DFAN14A

SYNAPTIC PHARMACEUTICAL CORP
Form DFAN14A
November 22, 2002

SCHEDULE 14A

SCHEDULE 14A INFORMATION

PROXY STATEMENT PURSUANT TO SECTION 14(A)
OF THE SECURITIES EXCHANGE ACT OF 1934

Filed by the Registrant []

Filed by a Party other than the Registrant [X]

Check the appropriate box:

- [] Preliminary Proxy Statement
- [] Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- [] Definitive Proxy Statement
- [] Definitive Additional Materials
- [X] Soliciting Material Pursuant to Section 240.14a-12

SYNAPTIC PHARMACEUTICAL CORPORATION

(Name of Registrant as Specified in its Charter)

H. LUNDBECK A/S

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- [X] No fee required.
- [] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies:
 - (2) Aggregate number of securities to which transaction applies:
 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 - (4) Proposed maximum aggregate value of transactions:
 - (5) Total fee paid:

-
- [] Fee paid previously with preliminary materials.
 - [] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - (1) Amount Previously Paid:
 - (2) Form, Schedule or Registration Statement No.:
 - (3) Filing Party:
 - (4) Date Filed:

Edgar Filing: SYNAPTIC PHARMACEUTICAL CORP - Form DFAN14A

2

Set forth as Exhibit 99.1 is the text of a press release issued by H. Lundbeck A/S on November 21, 2002.

THIS FILING IS IDENTICAL TO THE FILING MADE ON NOVEMBER 21, 2002 (ACCESSION NUMBER 0000950157-02-000793). THIS FILING IS BEING MADE TODAY FOR THE SOLE PURPOSE OF CORRECTLY INDEXING THE FILING TO H. LUNDBECK A/S'S APPROPRIATE EDGAR CENTRAL INDEX KEY (CIK) CODE.

Information Regarding Participants on behalf of Lundbeck

Set forth below is the name, business address, principal occupation or employment and citizenship of each director and executive officer of Lundbeck. The name of each person who is a director of Lundbeck is marked with an asterisk. The business address of each person listed below is 9 Ottiliavej, DK-2500 Valby, Copenhagen, Denmark. As of the date of this filing, none of the directors or executive officers listed below individually held any options or shares of Synaptic securities.

Name and Business Address	Principal Occupation or Employment	Citizenship
ERIK SPRUNK-JANSEN	President and Chief Executive Officer of Lundbeck	Denmark
CLAUS BRAESTRUP	Executive Vice President, Research and Development of Lundbeck	Denmark
LARS BANG	Senior Vice President, Commercial Operations, Europe and Overseas of Lundbeck	Denmark
HARALD CONRADI-LARSEN	Senior Vice President, Human Resource Management of Lundbeck	Norway
STIG LOKKE PEDERSEN	Senior Vice President, Corporate Affairs and Commercial Operations, America and Asia of Lundbeck	Denmark
HANS HENRIK MUNCH-JENSEN	Senior Vice President, Corporate Finance and Communication of Lundbeck	Denmark
OLE MOESTRUP	Senior Vice President, Strategic Marketing of Lundbeck	Denmark
MORTEN KOLD MIKKELSEN	Senior Vice President, Supply Operations and Engineering of Lundbeck	Denmark
ARNE V. JENSEN*	Chairman	Denmark
OLE STEEN ANDERSEN	Executive Vice President, Chief Financial Officer of Danfoss	Denmark

Edgar Filing: SYNAPTIC PHARMACEUTICAL CORP - Form DFAN14A

LARS BRUHN*	President and Chief Executive Officer of Bruhn Group	Denmark
PETER KURSTEIN*	Executive Vice President of Radiometer Medical	Denmark
SVEN DYRLOV MADSEN*	Director	Denmark
OLE VAHLGREN*	Vice President, U.S. Operations of Lundbeck, Inc.	Denmark
FLEMMING LINDELOV*	Chief Executive Officer of Royal Scandinavia	Denmark
JAN GOTTLIEBSEN*	Teamleader Liquid & Sterile Production of Lundbeck	Denmark
BIRGIT BUNDBAARD ROSENMEIER*	Head of Department, Quality Sterile Production of Lundbeck	Denmark
TORBEN SKARFELDT*	Head of Department, Corporate Licensing of Lundbeck	Denmark

3

INDEX TO EXHIBITS

Exhibit No.	Exhibit
99.1	Press Release issued by H. Lundbeck A/S on November 21, 2002.